| Mrs Michele Herbert, APRN | |
|
4305 New Shepherdsville Rd, Bardstown, KY 40004-9019 | |
| (502) 350-5000 | |
| Not Available |
| Full Name | Mrs Michele Herbert |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 10 Years |
| Location | 4305 New Shepherdsville Rd, Bardstown, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083005516 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2200X | Nurse Practitioner - Adult Health | 3009198 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Flaget Memorial Hospital | Bardstown, KY | Hospital |
| Hardin Memorial Hospital | Elizabethtown, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cogent Healthcare Of Kentucky, Psc | 0648294157 | 67 |
| Baptist Health Medical Group Inc | 5597867184 | 1912 |
News Archive
Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa's RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
Researchers of Kaunas University of Technology, the Lithuanian University of Health Sciences and Italian high-tech company Gruppo Fos Lithuania are developing innovative technology for the personalized care of the patients who have experienced a stroke.
It is crucial to differentiate between benign and malignant ovarian cysts and tumours in a fast and reliable manner. This improves the surgical management and prognosis of the patient.
Scientists at the Leibniz Institute for Molecular Pharmacology in Berlin-Buch and the California Institute of Technology in Pasadena cooperate in the future for the development of the latest biosensors for usage related to personalized medicine and drug development.
› Verified 7 days ago
| Entity Name | Cogent Healthcare Of Kentucky, Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053362293 PECOS PAC ID: 0648294157 Enrollment ID: O20060124000434 |
News Archive
Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa's RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
Researchers of Kaunas University of Technology, the Lithuanian University of Health Sciences and Italian high-tech company Gruppo Fos Lithuania are developing innovative technology for the personalized care of the patients who have experienced a stroke.
It is crucial to differentiate between benign and malignant ovarian cysts and tumours in a fast and reliable manner. This improves the surgical management and prognosis of the patient.
Scientists at the Leibniz Institute for Molecular Pharmacology in Berlin-Buch and the California Institute of Technology in Pasadena cooperate in the future for the development of the latest biosensors for usage related to personalized medicine and drug development.
› Verified 7 days ago
| Entity Name | University Medical Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861554438 PECOS PAC ID: 0042123598 Enrollment ID: O20110204000012 |
News Archive
Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa's RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
Researchers of Kaunas University of Technology, the Lithuanian University of Health Sciences and Italian high-tech company Gruppo Fos Lithuania are developing innovative technology for the personalized care of the patients who have experienced a stroke.
It is crucial to differentiate between benign and malignant ovarian cysts and tumours in a fast and reliable manner. This improves the surgical management and prognosis of the patient.
Scientists at the Leibniz Institute for Molecular Pharmacology in Berlin-Buch and the California Institute of Technology in Pasadena cooperate in the future for the development of the latest biosensors for usage related to personalized medicine and drug development.
› Verified 7 days ago
| Entity Name | Baptist Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922401611 PECOS PAC ID: 5597867184 Enrollment ID: O20150219000942 |
News Archive
Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa's RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
Researchers of Kaunas University of Technology, the Lithuanian University of Health Sciences and Italian high-tech company Gruppo Fos Lithuania are developing innovative technology for the personalized care of the patients who have experienced a stroke.
It is crucial to differentiate between benign and malignant ovarian cysts and tumours in a fast and reliable manner. This improves the surgical management and prognosis of the patient.
Scientists at the Leibniz Institute for Molecular Pharmacology in Berlin-Buch and the California Institute of Technology in Pasadena cooperate in the future for the development of the latest biosensors for usage related to personalized medicine and drug development.
› Verified 7 days ago
| Entity Name | Hospitalist Medicine Physicians Of Indiana Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720416555 PECOS PAC ID: 7719119965 Enrollment ID: O20210719003483 |
News Archive
Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa's RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
Researchers of Kaunas University of Technology, the Lithuanian University of Health Sciences and Italian high-tech company Gruppo Fos Lithuania are developing innovative technology for the personalized care of the patients who have experienced a stroke.
It is crucial to differentiate between benign and malignant ovarian cysts and tumours in a fast and reliable manner. This improves the surgical management and prognosis of the patient.
Scientists at the Leibniz Institute for Molecular Pharmacology in Berlin-Buch and the California Institute of Technology in Pasadena cooperate in the future for the development of the latest biosensors for usage related to personalized medicine and drug development.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Michele Herbert, APRN 5901-c Peachtree Dunwoody Rd, Ste 350, Atlanta, GA 30328-5661 Ph: (678) 441-8500 | Mrs Michele Herbert, APRN 4305 New Shepherdsville Rd, Bardstown, KY 40004-9019 Ph: (502) 350-5000 |
News Archive
Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa's RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
Researchers of Kaunas University of Technology, the Lithuanian University of Health Sciences and Italian high-tech company Gruppo Fos Lithuania are developing innovative technology for the personalized care of the patients who have experienced a stroke.
It is crucial to differentiate between benign and malignant ovarian cysts and tumours in a fast and reliable manner. This improves the surgical management and prognosis of the patient.
Scientists at the Leibniz Institute for Molecular Pharmacology in Berlin-Buch and the California Institute of Technology in Pasadena cooperate in the future for the development of the latest biosensors for usage related to personalized medicine and drug development.
› Verified 7 days ago
Angela Marie Ballard, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 201 S 5th St, Bardstown, KY 40004 Phone: 502-348-5968 Fax: 502-349-0963 | |
Mr. Justin William Davis, MSN, APRN, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 110 W John Rowan Blvd, Bardstown, KY 40004 Phone: 502-337-7409 | |
Mrs. Shandrika Renee Feitelson, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4305 New Shepherdsville Rd, Bardstown, KY 40004 Phone: 502-350-5000 | |
Mrs. Monica B Strenecky, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 201 S 5th St, Bardstown, KY 40004 Phone: 502-348-6309 Fax: 502-348-2793 | |
Kathleen Troutman, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 110 W John Rowan Blvd, Bardstown, KY 40004 Phone: 502-337-7409 | |
Kali M Lewis, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 201 S 5th St, Bardstown, KY 40004 Phone: 502-348-6309 Fax: 502-348-2793 |